Exploring anti-malarial potential of FDA approved drugs: an in silico approach by Ramakrishnan, Gayatri et al.
Ramakrishnan et al. Malar J  (2017) 16:290 
DOI 10.1186/s12936-017-1937-2
RESEARCH
Exploring anti-malarial potential of FDA 
approved drugs: an in silico approach
Gayatri Ramakrishnan1,3,4, Nagasuma Chandra2 and Narayanaswamy Srinivasan3* 
Abstract 
Background: The critically important issue on emergence of drug-resistant malarial parasites is compounded by 
cross resistance, where resistance to one drug confers resistance to other chemically similar drugs or those that share 
mode of action. This aspect requires discovery of new anti-malarial compounds or formulation of new combination 
therapy. The current study attempts to contribute towards accelerating anti-malarial drug development efforts, by 
exploring the potential of existing FDA-approved drugs to target proteins of Plasmodium falciparum.
Methods: Using comparative sequence and structure analyses, FDA-approved drugs, originally developed against 
other pathogens, were identified as potential repurpose-able candidates against P. falciparum. The rationale behind 
the undertaken approach is the likeliness of small molecules to bind to homologous targets. Such a study of evolu-
tionary relationships between established targets and P. falciparum proteins aided in identification of approved drug 
candidates that can be explored for their anti-malarial potential.
Results: Seventy-one FDA-approved drugs were identified that could be repurposed against P. falciparum. A total of 
89 potential targets were recognized, of which about 70 are known to participate in parasite housekeeping machin-
ery, protein biosynthesis, metabolic pathways and cell growth and differentiation, which can be prioritized for chemo-
therapeutic interventions. An additional aspect of prioritization of predicted repurpose-able drugs has been explored 
on the basis of ability of the drugs to permeate cell membranes, i.e., lipophilicity, since the parasite resides within a 
parasitophorous vacuole, within the erythrocyte, during the blood stages of infection. Based on this consideration, 46 
of 71 FDA-approved drugs have been identified as feasible repurpose-able candidates against P. falciparum, and form 
a first-line for laboratory investigations. At least five of the drugs identified in the current analysis correspond to exist-
ing antibacterial agents already under use as repurposed anti-malarial agents.
Conclusions: The drug-target associations predicted, primarily by taking advantage of evolutionary information, 
provide a valuable resource of attractive and feasible candidate drugs that can be readily taken through further stages 
of anti-malarial drug development pipeline.
Keywords: Antimalarial agents, Drug repurposing, Drug targets, Plasmodium falciparum, Sequence analysis
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Over the past decade, extensive measures have been 
undertaken to prevent or cure malaria, resulting in 
reduction of mortality rates by 60% [1]. Despite the 
tremendous progress, malaria continues to be a global 
burden with 214 million new incidences and about 
0.4  million deaths in the year 2015 alone, the primary 
cause of which is the emergence of drug-resistant strains 
of Plasmodium falciparum. The current anti-malarial 
regimens include several drugs administered either 
alone or in combination, which can be grouped based 
on their drug class, as summarized in Table  1. Albeit 
moderately effective, the current treatment regimens 
remain inadequate due to sub-optimal safety profile in 
some cases, as described in Table 1, and mainly due to 
emergence of drug-resistant parasites. Anti-malarial 
drug resistance, mainly contributed by transporters in 
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the parasite [2], is also compounded by ‘cross resistance’, 
where resistance to one drug confers resistance to other 
chemically similar drugs or those that share mode of 
action. The current attempt to prevent development of 
resistance to artemisinin, a potent first-line anti-malar-
ial agent, includes administration of artemisinin-based 
combination therapy (ACT) [1], i.e., artemisinin with 
non-artemisinin partners, such as amodiaquine and 
mefloquine (Table 1). However, resistance to almost all 
known anti-malarial agents has reportedly emerged [3, 
4] limiting combinatorial therapy as well. This necessi-
tates the discovery and development of either new anti-
malarial agents or unexplored combination of drugs 
that may not only reduce mortality and morbidity of the 
disease, but also reduce the risk of resistance to anti-
malarial drugs.
Identifying new therapeutic uses of existing drugs has 
become an attractive practicable strategy due to signifi-
cant advantages in cost and time involved in the drug 
development pipeline. Indeed, this strategy has been 
exploited previously, which led to the formulation of 
anti-malarial treatment regimens that include anti-bac-
terials such as sulfonamides, tetracyclines, clindamy-
cin and azithromycin [5]. Albeit successful earlier as a 
part of combination therapy, these anti-bacterials have 
become inefficient due to emergence of drug-resistant 
parasites. Recently, high-throughput chemical library 
screening initiatives have been useful in identification 
of repurpose-able drugs that await evaluation on their 
anti-malarial efficacy [6, 7]. With the lack of adequate 
anti-malarial treatment regimen and increasing inci-
dences of drug-resistant parasites, exploring existing 
drugs for use against malaria is gaining rapid impor-
tance [8]. The current study makes an effort to contrib-
ute towards the same with the use of FDA-approved 
drugs.
Using the concept of within-target-family selec-
tivity of small molecules [9], i.e., the likeliness of a 
small-molecule to bind to related targets, potential 
repurpose-able drug candidates against malaria could 
be recognized by means of exploration of evolution-
ary relationships between targets of FDA-approved 
Table 1 Details on current anti-malarial agents
DrugBank (v.4.3) [26]. The drugs highlighted in italics denote anti-bacterials repurposed for use against malaria
Drug name Drug class Anti-malarial activity Side effects
Quinine Cinchona alkaloids Accumulates in food vacuoles and 
forms toxic haem complexes
Side effects include hearing impairment, 
rashes, vertigo, vomiting and in some cases 
neurotoxicity
Quinidine
Mefloquine Quinolines and derivatives Nausea, dizziness, diarrhoea, bradycardia and 
neurotoxicity
Chloroquine May cause psoriasis
Amodiaquine Vomiting, dizziness and in some cases hepatic 
disorders
Primaquine Believed to block oxidative 
metabolism in the parasite
Anorexia, vomiting, cramps and anaemia
Halofantrine Phenanthrenes and derivatives Causes parasite membrane 
damage by forming cytotoxic 
complexes
Nausea, diarrhoea, itching and high cardiotoxic-
ity
Sulfadoxine Benzene and substituted deriva-
tives
Inhibit synthesis of folates Skin reactions (rare)
Sulfamethoxypyridazine
Proguanil Very few: hair loss and mouth ulcers
Pyrimethamine Diazines Occasional rashes
Tetracycline Tetracyclines Inhibits translation –
Doxycycline Depression of bone growth and gastrointestinal 
disturbances
Clindamycin Carboxylic acids and derivatives Inhibits protein synthesis Nausea, vomiting and cramps
Azithromycin Macrolides and analogues May cause angioedema and jaundice
Artemisinin Lipids and lipid-like molecules Believed to affect mitochondrial 
electron transport chain [46] or 
disrupt cellular redox cycling or 
inhibition of haem metabolism 
[47]
Nausea, anorexia, dizziness and neurotoxicity
Atovaquone Naphthalenes Affects mitochondrial electron 
transport chain
May cause rashes, diarrhoea and headache
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drugs and P. falciparum proteins. An initial filter to 
exclude drugs known to target human proteins aided 
in elimination of drugs with undesirable pharmacologi-
cal potential. This drug-target identification methodol-
ogy facilitated recognition of 89 P. falciparum proteins 
which could serve as targets for 71 FDA-approved 
drugs. The drug-target associations thus predicted can 
serve as a useful resource for experimental endeavours 
in the light of anti-malarial drug development and drug 
discovery.
Methods
Dataset
Information on gene products encoded in the genome of 
P. falciparum 3D7 isolate was obtained from PlasmoDB 
(release 24) [10]. Proteins annotated as pseudogenes were 
excluded as such entries correspond to genes that appar-
ently lack protein-coding ability and are unlikely to be 
expressed in the cell. The protein sequences correspond-
ing to 5400 protein-coding genes were thus retrieved from 
the database. Furthermore, protein expression profiles of 
the parasite proteins during their developmental stages in 
human were extracted from the published works of Pease 
et al. [11], Florens et al. [12] and Le Roch et al. [13] for intra-
erythrocytic stages (ring, trophozoite, schizont, merozoite), 
from Lindner et al. [14] for liver stage (sporozoite), and from 
Silvestrini et al. [15] for the final gametocyte stage. Details 
on FDA-approved drugs (1634) and the associated protein 
targets (1573) were obtained from DrugBank (version 4.3), 
an extensive resource on drug and target information.
Approach to recognize potential drug-target interactions
The protocol adopted to identify FDA-approved drugs 
that can be repurposed against proteins in P. falciparum 
is similar to the protocol employed in an earlier published 
report on repurposing drugs against Mycobacterium 
tuberculosis H37Rv [16]. The exclusion of drugs known 
to be effective against human proteins and the exclu-
sion of anti-malarial agents currently in use (Table  1) 
formed the initial step of the approach. Also, only those 
drugs that hold evidence on pharmacological validation 
against established targets were considered. Thus, 196 
FDA-approved drugs associated with 138 protein targets 
were considered for subsequent analysis. The likelihood 
of drugs to be active as potential anti-malarial agents is 
dependent on the similarity of known targets to P. fal-
ciparum proteins. To recognize target-related proteins 
in P. falciparum, an iterative sequence search program, 
jackhammer availed through HMMER3.0 suite [17], was 
employed at an E-value cut-off of 0.0001 and five rounds 
of iteration. An alignment coverage cut-off of 70% or an 
alignment encompassing at least one functional and/or 
structural domain was used as an additional criterion to 
eliminate unreliable hits characterized by short stretches 
of alignment.
Once reliable target-related proteins are recognized 
in P. falciparum, a comparative structural analysis was 
undertaken to pinpoint probable drug-binding sites in 
the parasite proteins, based on information on ligand-
binding sites in the known targets. Structural infor-
mation for target proteins and parasite proteins was 
obtained from PDB (Protein Data Bank). For parasite 
proteins of no known structure, structural models were 
retrieved from ModBase [18] or built using MODELLER 
v.9.14 [19]. The structural models obtained were checked 
for reliability based on z-DOPE (Discrete Optimized 
Protein Energy) score [20] (<0), ModPipe Quality Score 
(MPQS) cut-off of 1.1 and query coverage threshold of 
80% or a query coverage of at least one functional and/
or structural domain. Comparative evaluation of binding 
sites across established targets and their homologues in 
P. falciparum was pursued depending on the availability 
of crystal structures of ligand-bound targets. A struc-
tural alignment algorithm, TM-align [21], was employed 
to assess the extent of conservation of residues in local 
aligned regions between the parasite proteins and corre-
sponding related targets. A TM-score cut-off of 0.5 was 
used, which typically implies convincing structural simi-
larity of the proteins aligned [22]. In certain cases, a reli-
able structural model for the P. falciparum protein or its 
domain could not be built, primarily due to abundance 
of low-complexity regions in the protein and/or presence 
of non-conserved inserts within the functional domains. 
Indeed, these features contribute to the pronounced 
sequence divergence observed in genome of P. falcipa-
rum [23–25]. Thus, in such cases, the aligned regions of 
interest between the protein sequences of P. falciparum 
and related targets were manually examined to infer fea-
sibility of drug-target interactions in P. falciparum. Simi-
larly, in the absence of crystal structures of established 
targets, potential drug-target interactions in the parasite 
proteins were conjectured on the basis of alignment of 
functionally relevant regions.
Results
Plasmodium falciparum homologues of established 
targets of FDA-approved drugs were identified using 
sequence and structural analyses described in “Methods”. 
If P. falciparum homologue of a known drug target could 
be identified, the drug concerned is an attractive possibil-
ity for anti-malarial activity.
Potential repurpose-able drug candidates
A total of 71 FDA-approved drugs, predominantly con-
stituted by antibacterial agents (56), were recognized 
as repurpose-able candidates against 89 P. falciparum 
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proteins. The complete list of predicted drug-target asso-
ciations is provided in Additional file  1. At least five of 
the anti-malarial drugs listed in Table 1 are anti-bacterial 
and have been repurposed for use against malaria. Based 
on hierarchical, rule-based, structural classification of 
drugs, as obtained from DrugBank [26], the 71 drugs 
could be grouped into 22 drug classes. Figure 1 outlines 
the distribution of 71 drugs under the 22 classes, along 
with number of predicted parasite targets associated 
with each drug class. The predominance of antibacterial 
agents, represented as green coloured bars, can be readily 
inferred from the Figure. Notably, a number of instances 
can be observed in the Figure, which corresponds to 
drugs with polypharmacological potential, i.e., the abil-
ity to act on multiple targets. The most striking example 
in the Figure is that of two antibacterial drugs (DB00410: 
mupirocin, DB00548: azelaic acid) under the class ‘Fatty 
acyls’ which have been predicted to target 21 parasite 
proteins; of which nine parasite proteins involved in ami-
noacylation are potential targets for mupirocin and 12 
metabolic proteins of the parasite are potential targets for 
azelaic acid.
Azelaic acid is a naturally occurring compound pro-
duced by Malassezia furfur, and is approved for use as a 
topical antibacterial agent. This drug is believed to inhibit 
several metabolic enzymes in bacteria, including tyrosi-
nase, mitochondrial enzymes of the respiratory chain, 
thioredoxin reductase, 5-α-reductase and DNA poly-
merase. Indeed, the 12 potential targets recognized in P. 
falciparum belong to these categories of oxido-reductive 
enzymes, four of which are localized in a vital organelle of 
the parasite, the apicoplast (highlighted in Table 2). Con-
sidering the ability to target multiple metabolic enzymes, 
azelaic acid forms an attractive repurpose-able candidate 
against P. falciparum. Such polypharmacological drugs 
have the ability to stand tolerance against development 
of drug resistance in malarial parasites, and indeed are of 
immense interest in rationalizing anti-malarial drug dis-
covery and development efforts. Table 2 summarizes the 
details on the predicted targets of azelaic acid.
Mupirocin, an antibiotic isolated from Pseudomonas 
fluorescens, is one of the widely used bacteriocidal agent 
known to inhibit isoleucyl-tRNA synthetase (also known 
as isoleucyl-tRNA ligase). Recently, a study demonstrated 
the potent inhibitory activity of mupirocin against blood-
stage P. falciparum [27]. Despite its effectiveness, mupi-
rocin is unfit to serve as a lead for anti-malarial therapy 
as it is restricted to topical usage due to rapid hydroly-
sis in body fluids. Nevertheless, non-hydrolysable mupi-
rocin analogues with evidence on inhibitory activity can 
be explored for their potential use against P. falciparum. 
Indeed, two analogues of mupirocin, CHEMBL38412 
and CHEMBL315230, were identified from an earlier 
published study [16] where two-step in silico screen-
ing (two-dimensional followed by three-dimensional 
molecular similarity calculations) was employed on a set 
of FDA-approved drugs against a database of ChEMBL 
compounds [28, 29], which hosts exhaustive details on 
drug-like bioactive compounds largely extracted from 
literature and other databases. Of the two mupirocin 
analogues CHEMBL38412 and CHEMBL315230, which 
are experimentally verified inhibitors of isoleucyl-tRNA 
Fig. 1 Distribution of drug-target associations in the context of drug classes. The distribution of 71 drugs, identified in the study, according to their 
drug classes is represented in the form of a bar chart (front); the bars are coloured based on the organisms the drugs are known to be active against: 
antibacterial (green), antiviral (orange), anthelmintic (blue), and antifungal (red). A bar graph representation of the number of P. falciparum targets 
(light brown) predicted to be associated with each drug class is also shown
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synthetase [30, 31], CHEMBL38412 is reportedly a non-
hydrolysable analogue of mupirocin and exhibits similar 
antibacterial activity in vitro as mupirocin [30]. Elucida-
tions on binding site and binding pose of CHEMBL38412 
can be readily inferred based on structural similarity 
between mupirocin-bound isoleucyl-tRNA synthetase 
and related parasite proteins (Table  2 and Additional 
file  2: Figure S1) and the extent of molecular similarity 
between the drug and its analogue as illustrated in Fig. 2. 
Based on reasonable structural similarity amongst related 
proteins as well as the compounds, the mupirocin ana-
logue CHEMBL38412 forms an attractive lead and thus 
can be investigated further for its anti-malarial activity.
Several other drug classes corresponding to drugs 
with possible polypharmacological potential, as deline-
ated in Fig.  1, can be investigated further. Figure  1 also 
illustrates populated drug classes including ‘Quinolines’, 
‘Carbohydrate conjugates’, ‘Benzene derivatives’ and 
‘Imidazopyrimidines’ with relatively fewer predicted 
targets associated with them. Indeed, this observation 
implies the possibility of combination therapy. But the 
risk of cross-resistance exists, where resistance to one 
drug may confer resistance to other chemically similar 
drugs or those drugs that share similar mechanism of 
action. Reports on tetracycline and doxycycline resist-
ance, alone or in combination with other drugs, limits 
the possibility of using approved drugs chemically similar 
to tetracycline. Seven such drugs (DB00595: oxytetracy-
cline, DB01301: rolitetracycline, DB00618: demeclocy-
cline, DB00256: lymecycline, DB00453: clomocycline, 
DB01017: minocycline, DB00560: tigecycline) in the 
drug class ‘Tetracyclines’ were recognized in the current 
analysis as potential drug candidates against ten potential 
parasite targets (Fig.  1). Thorough experimental investi-
gations are necessary to ascertain the likelihood of these 
drugs as repurpose-able candidates.
Drug targets recognized in Plasmodium falciparum
The 89 potential targets identified in P. falciparum could 
be categorized under six functional classes, including 
Fig. 2 Mupirocin and its analogue. Two-dimensional chemical representations of the drug mupirocin and its analogue CHEMBL38412 is shown. 
The presence of non-hydrolysable ester group at C1 position in CHEMBL38412 is depicted with an arrow in green. This figure was generated using 
Marvin 15.5.18, 2015, ChemAxon [45]
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protein biosynthesis, metabolic processes, DNA-
dependent activities, microtubule-associated processes, 
transport and proteolytic activities, most of which are 
expressed in all six life-cycle stages of infection in human 
host. Figure  3 illustrates the distribution of predicted 
targets across the six life-cycle stages of P. falciparum 
binned under six functional categories. As shown in 
Fig.  3, 38 of 89 predicted targets participate in cellular 
protein synthesis, which are predominantly expressed 
in all six life-cycle stages of the parasite. This category 
includes proteins participating in aminoacylation and 
protein translation, essential for housekeeping activi-
ties. Other proteins of parasite housekeeping machin-
ery including DNA polymerases, DNA topoisomerases, 
DNA gyrases, microtubules and structural constituents 
of cytoskeleton, qualify as attractive targets as these P. 
falciparum proteins expressed in all six life-cycle stages 
during infection in humans play a significant role in reg-
ulating rate of translation, cell growth and cell develop-
ment [12, 23]. Thus, targeting such parasite proteins (64) 
belonging to the functional classes ‘Protein biosynthesis’, 
‘DNA-dependent processes’ and ‘Microtubule-associated’ 
(Fig. 3) can impede growth and transition between differ-
ent developmental stages of the parasite. Based on the 
current analysis, a list of 46 drugs were identified, most 
of which are antibacterial agents, predicted to target 64 
proteins involved in parasite housekeeping machinery 
(Additional file 1).
An important characteristic of P. falciparum is its abil-
ity to undergo vast re-organization of metabolic make-up 
during the course of its life cycle in multiple host envi-
ronments. Inhibition of critically important metabolic 
enzymes can be detrimental for the parasite’s survival, 
one of which is the glycolytic enzyme lactate dehydro-
genase (pfLDH) essential for intra-erythrocytic growth 
of the parasite [32], recognized as a target for the drug 
nitrofural (DB00336) in the current analysis. Studies on 
pfLDH have reported a distinct nature of NADH bind-
ing pocket [32] where the anti-malarial chloroquine is 
believed to bind competitively [33]. Nitrofural, a potent 
antibacterial agent, is known to inhibit several bacterial 
enzymes involved in aerobic and anaerobic degrada-
tion of glucose and pyruvate. Crystal structure of nitro-
fural-bound nitroreductase enzyme in Escherichia coli 
Fig. 3 Functional relevance of the predicted targets. The distribution of 89 potential targets under six functional categories expressed in six life-
cycle stages is represented as a stacked bar chart. The absolute number of proteins under each functional category is indicated in brackets, while the 
numbers in stacked bars denote the number of proteins, which are upregulated in a life-cycle stage in each functional category
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demonstrated the accommodation of the drug in the 
cofactor binding site [34]. Thus, the cofactor binding site 
in the crystal structure of pfLDH, i.e., the NADH bind-
ing pocket, along with adjacent solvent exposed cavities, 
were used as receptor grids to dock nitrofural using Glide 
(Grid-based ligand docking with energetics) [35–37] 
and assess the predicted binding energy and binding 
pose of the approved drug. Using Glide XP (extra pre-
cision) scoring function [37], the predicted binding site 
of the drug nitrofural was evaluated. Figure 4 illustrates 
the docked pose of nitrofural, achieved with a best pos-
sible energy score of −6.97 kcal/mol, at the NADH bind-
ing pocket of pfLDH. The docked drug was identified 
to make contacts with critical residues of pfLDH that 
are involved in cofactor binding, including Asp53 and 
Thr97 (Fig. 4c, d), implying the likeliness of nitrofural in 
inhibiting the glycolytic enzyme of the parasite. In addi-
tion to pfLDH, six P. falciparum metabolic proteins, 
including malate dehydrogenase (PF3D7_0618500), 
lactate dehydrogenase (PF3D7_132520), lipoam-
ide dehydrogenase (PF3D7_0815900), thiore-
doxin reductase (PF3D7_0923800), dihydrolipoyl 
dehydrogenase (PF3D7_1232200), and glutathione 
reductase (PF3D7_1419800), several of which are essen-
tial for the parasite’s growth during intra-erythrocytic 
development stages, were recognized as potential targets 
Fig. 4 Targeting pfLDH. a Surface representation of crystal structure of pfLDH bound with its native substrate NADH, represented as sticks, is shown 
(PDB:1LDG). b Surface representation of crystal structure of pfLDH with docked nitrofural, in sticks, is shown. The details of the residues of pfLDH 
involved in interaction with its native substrate are illustrated in c and with the nitrofural in d. For convenience, only those residues are shown in 
stick representation which are common to binding substrate and the predicted drug
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for nitrofural. Considering such a polypharmacologi-
cal potential of nitrofural, further experimental investi-
gations on this FDA-approved drug can reveal insights 
into its usefulness as an anti-malarial agent. Other met-
abolic enzymes identified as targets include enoyl-acyl 
carrier reductase, dihydropteroate synthetase, thiore-
doxin reductase, bifunctional dihydrofolate reduc-
tase–thymidylate synthase, and other oxido-reductive 
enzymes which have been regarded as attractive tar-
gets for anti-malarial drug development [38], many of 
which are expressed in all six stages of the parasite’s life 
cycle (Fig.  3). The identification of such pharmaceuti-
cally relevant metabolic proteins justifies the strength of 
the approach used and thus, the feasibility of approved 
drugs predicted to target such proteins can be further 
investigated.
Plasmodium falciparum comprises a relict-plastid, 
termed as the apicoplast, which is indispensable for the 
parasite’s growth and typically contains a range of meta-
bolic pathways and housekeeping processes that differ 
from those in human hosts [39]. Thus, parasite proteins 
pertaining to the apicoplast present ideal strategies for 
drug design. Of 89 predicted targets, 29 were identified 
as constituents of apicoplast—8 metabolic enzymes and 
21 involved in housekeeping machinery. These entries are 
highlighted in Additional file  1. Information on subcel-
lular localization of other parasite proteins was obtained 
from Malaria Metabolic Pathways database [40]. Fig-
ure 5 illustrates the distribution of number of predicted 
targets in terms of their subcellular localization in P. fal-
ciparum (inner ring), along with information on upreg-
ulated, intra-erythrocytic stage-specific expression of 
associated proteins (outer ring). As shown in Fig. 5, more 
than half of the predicted P. falciparum targets are local-
ized in subcellular organelle: nucleus, apicoplast and 
mitochondrion.
While recognition of proteins essential for the growth 
and survival of the parasite as targets gains significance, 
targeting such proteins may be challenging as the parasite 
resides within the erythrocytes, and additionally, within 
a protective encasing of parasitophorous vacuole, dur-
ing blood stages of infection. To reach a target localized 
in an organelle in the parasite during its intra-erythro-
cytic development stages, a drug is required to perme-
ate at least four membranes: erythrocyte cell membrane 
>parasitophorous vacuole membrane >P. falciparum cell 
membrane >organellar membrane. It is thus of impor-
tance to consider lipophilicity of the drugs, i.e., the ability 
of the compounds to dissolve in lipophilic or non-aque-
ous solutions, which in turn determines the ADMET 
(absorption, distribution, metabolism, excretion, toxic-
ity) properties of the drug and the likelihood of its thera-
peutic success [41]. Lipophilicity is typically measured in 
terms of logarithm of partition coefficient (logP), which 
is the ratio of concentrations of a compound between 
two phases:non-aqueous:octanol and aqueous:water. 
According to Lipinski’s rule of five [42], logP value of 
an active compound should be no more than five, i.e., a 
concentration difference of 1:100,000 between water and 
octanol phases. A desirable compound should neither be 
too lipophilic (logP  >  5) nor be too hydrophilic (low or 
negative logP), for adequate absorption or permeation 
across cellular membranes. Information on experimen-
tally determined logP values of 71 FDA-approved drugs 
was obtained from DrugBank. Forty-six of 71 drugs were 
recognized which satisfied the logP value criterion in an 
optimal range of (0–5). These drugs are speculated to 
be active against P. falciparum during the symptomatic 
blood stages of infection, and therefore can be prioritized 
to formulate chemotherapeutic regimen against malaria. 
Table 3 summarizes the details of 46 FDA-approved drugs 
that have the potential to influence anti-malarial drug 
development. Several of the 46 practicable set of drugs, 
approved for use against other pathogenic infections, have 
been exploited for their use as anti-malarial agents, exam-
ined either in vitro or in vivo (Table 3). Such concurring 
instances justify the strength of the protocol followed.
The predictions were compared with previously pub-
lished studies on recognizing anti-malarial potential of 
approved drugs [8, 43]. Nine drug-target associations 
were identified pertaining to apicoplast proteins and 
anti-tubercular drugs (rifamixin, rifampicin) concurring 
with the predictions made in the current study which, in 
addition to the set of drugs mentioned in Table 3, can be 
readily taken through further stages of anti-malarial drug 
development pipeline.
Conclusion
An established concept of within-target-family selectiv-
ity of small molecules has been pursued which led to the 
recognition of 71 FDA-approved drugs that can be repur-
posed against 89 P. falciparum proteins. The framework 
on drug-target identification methodology established 
in an earlier published study [16], served as a guiding 
tool for the workflow adopted. An initial step on exclu-
sion of drugs active against human proteins, minimize 
the chance of obtaining drugs of undesirable pharma-
cological potential. Recognition of polypharmacological 
drugs, capable of targeting multiple proteins, are of great 
interest for parasites such as P. falciparum, as such drugs 
can stand tolerance against development of drug resist-
ance. Indeed, the majority of the drugs identified have 
the potential to target multiple parasite proteins. About 
70 of 89 potential targets identified in the current analy-
sis, are known to participate in parasite housekeeping 
machinery, protein biosynthesis, metabolic pathways, 
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and cell growth and differentiation. The drug-target asso-
ciations corresponding to such parasite targets of inter-
est can be investigated further for therapeutic relevance. 
While the approach undertaken provides a set of promis-
ing drug candidates and potential P. falciparum targets, 
it is limited in terms of evaluation of quantitative drug-
target selectivity. Investigations focused on pharma-
cokinetics and pharmacodynamics of drugs thus form 
a pre-requisite to assess the risk of possible drug-target 
toxicity in humans, in addition to investigations on feasi-
bility of existing drugs as potential anti-malarials.
Considering the intra-erythrocytic growth of P. falcipa-
rum during the course of infection, an attempt has been 
made to prioritize the predicted repurpose-able FDA-
approved drugs on the basis of their ability to perme-
ate cell membranes, i.e., lipophilicity, since the parasite 
Fig. 5 Subcellular localization of predicted targets. The distribution of predicted targets based on their subcellular localization is delineated in the 
inner ring. The outer ring denotes number of associated proteins with up-regulated expression in each of the intra-erythrocytic stages, i.e., R ring, T 
trophozoite, Sc schizont and M merozoite
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resides within a parasitophorous vacuole in the erythro-
cyte. Using experimentally determined values of octanol–
water partition coefficient of drugs, it is estimated that 46 
of 71 drugs are feasible repurpose-able candidates against 
P. falciparum. These approved drugs can be readily pur-
sued further for an experimental follow-up in vivo.
Much of the drugs identified in the study as pro-
spective anti-malarial agents are antibiotics. The 
Table 3 Details on 46 FDA-approved drugs that are likely to be active against Plasmodium falciparum during the course 
of infection
Drug name DrugBank ID Category Drug class LogP
DB00199 Erythromycin [48] Antibacterial Macrolides and analogues 3.06
DB00218 Moxifloxacin Antibacterial Quinolines 2.9
DB00250 Dapsone [49]a Antibacterial Benzene derivatives 0.97
DB00256 Lymecycline Antibacterial Tetracyclines 0.3
DB00263 Sulfisoxazole [50] Antibacterial Benzene derivatives 1.01
DB00336 Nitrofural Antibacterial Furans 0.23
DB00400 Griseofulvin Antifungal Benzofurans 2.18
DB00410 Mupirocin [27] Antibacterial Fatty acyls 2.45
DB00426 Famciclovir Antiviral Imidazopyrimidines 0.6
DB00446 Chloramphenicol [51]b Antibacterial Carboxylic acids 1.14
DB00453 Clomocycline Antibacterial Tetracyclines 0.2
DB00487 Pefloxacin [52] Antibacterial Quinolines 0.27
DB00518 Albendazole [53] Anthelmintic Benzimidazoles 2.7
DB00537 Ciprofloxacin [52] Antibacterial Quinolines 0.28
DB00548 Azelaic acid Antibacterial Fatty acyls 1.57
DB00560 Tigecycline [54] Antibacterial Tetracyclines 0.8
DB00567 Cephalexin [55] Antibacterial Carboxylic acids 0.65
DB00576 Sulfamethizole Antibacterial Benzene derivatives 0.54
DB00609 Ethionamide Antitubercular Pyridines 0.5
DB00615 Rifabutin [56] Antitubercular Macrolactams 4.1
DB00618 Demeclocycline Antibacterial Tetracyclines 0.2
DB00730 Thiabendazole [53] Anthelmintic Benzimidazoles 2.47
DB00817 Rosoxacin Antibacterial Quinolines 3.0
DB01015 Sulfamethoxazole [57] Antibacterial Benzene derivatives 0.89
DB01017 Minocycline [55] Antibacterial Tetracyclines 0.05
DB01044 Gatifloxacin [58] Antibacterial Quinolines 2.6
DB01045 Rifampicin [56] Antitubercular – 2.7
DB01051 Novobiocin [52] Antibacterial Coumarins 4.1
DB01137 Levofloxacin [58] Antibacterial Quinolines 2.1
DB01155 Gemifloxacin Antibacterial Naphthyridines 2.3
DB01165 Ofloxacin [52] Antibacterial Quinolines 0.65
DB01208 Sparfloxacin [58] Antibacterial Quinolines 2.5
DB01220 Rifaximin Antibacterial Macrolactams 2.6
DB01256 Retapamulin Antibacterial Prenol lipids 4.37
DB01298 Sulfacytine Antibacterial Benzene derivatives 0.055
DB01321 Josamycin Antibacterial Macrolides and analogues 3.22
DB01361 Troleandomycin Antibacterial Macrolides and analogues 4.3
DB01581 Sulfamerazine Antibacterial Benzene and derivatives 0.14
DB01582 Sulfamethazine Antibacterial Benzene and derivatives 0.89
DB01603 Meticillin Antibacterial Lactams 1.22
DB01764 Dalfopristin [59] Antibacterial Macrolide lactams 1.58
DB02703 Fusidic acid [60] Antibacterial Steroid derivatives 4.42
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anti-malarial potential of antibiotics has been well-
documented in literature [44], several of which require 
to be administered in multiple doses in combination 
with other drugs. Owing to their unintended impact on 
host microbiome, use of multi-dose antibiotics perhaps 
should be restricted to patients with severe complica-
tions due to malaria and must only be considered after 
carefully weighing results from preclinical investigations 
and clinical trials. On similar lines, in the context of 
safety concerns, clues on FDA-approved drugs obtained 
from the prioritization exercise attempted in this study 
can be validated through experimental investigations 
for efficacy, toxicity, safety, and for the promising candi-
dates, also the therapeutic potential.
The present study provides a set of FDA-approved 
drugs that are likely to target proteins of the malarial 
parasite. Albeit, consideration of existing approved drugs 
can be time and cost-efficient in terms of accelerating 
anti-malarial drug development efforts, it is extremely 
important to realize that drug safety cannot be assumed 
for generic drugs. Indeed, it is imperative that safety 
of drugs for re-use as anti-malarial agents must be re-
assessed and concluded with a careful assessment of 
risk–benefit ratio for a given indication and duration of 
treatment.
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